Upper Aerodigestive Division, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA; email:
Annu Rev Med. 2019 Jan 27;70:425-435. doi: 10.1146/annurev-med-050217-025205. Epub 2018 Oct 24.
Early-stage non-small cell lung cancer is a potentially curable disease, but with relapse rates exceeding 50% with standard treatments, this is a patient population in critical need of therapy innovation. Immunotherapy with immune checkpoint blockade has revolutionized the treatment strategy for advanced lung cancer. However, the role of this therapy in earlier-stage disease is largely unknown. The study of immunotherapy in earlier-stage disease has many advantages, including assessment of pathologic response and incorporation of translational scientific analyses to evaluate antitumor immune responses. Multiple clinical trials are currently under way, with promising early results.
早期非小细胞肺癌是一种具有潜在可治愈性的疾病，但采用标准治疗后复发率超过 50%，因此该患者群体急需治疗创新。免疫检查点阻断的免疫疗法已经彻底改变了晚期肺癌的治疗策略。然而，这种疗法在早期疾病中的作用在很大程度上尚不清楚。免疫疗法在早期疾病中的研究具有许多优势，包括评估病理反应和纳入转化科学分析来评估抗肿瘤免疫反应。目前正在开展多项临床试验，早期结果令人鼓舞。
